Type of Mesothelioma:
Malignant pleural mesothelioma classification and survival prediction with CT imaging using ResNet
European Radiology 2025 October 30 [Link] Meng Zhou, Minghua Li, Qian Cao, Zhen Zhang, Leonard Wee, Andre Dekker, Ji Zhu, Haitao Jiang, Jiapeng Jiang, Xinyu Miao, Weimin Mao, Meng Yan, Hongyang Lu Abstract Objectives: This study aims to achieve accurate differentiation of malignant pleural mesothelioma (MPM) from metastatic pleural disease (MPD) and to predict the…
Read MoreRisk factors, prognostic factors, and nomograms for distant metastasis in patients with malignant pleural mesothelioma: A population-based retrospective study
The Journal of International Medical Research 2025 October [Link] Quzhe Lu, Chao Liu, Meixiang Xu, Zhi Hu, Hui Yin, Jie Yang Abstract Objectives Malignant pleural mesothelioma is a rare and aggressive thoracic tumor with a poor prognosis, wherein distant metastasis is associated with the lowest survival rates. It is imperative and emergent to construct nomograms…
Read MoreMalignant pleural mesothelioma classification and survival prediction with CT imaging using ResNet
European Radiology 2025 October 30 [Link] Meng Zhou, Minghua Li, Qian Cao, Zhen Zhang, Leonard Wee, Andre Dekker, Ji Zhu, Haitao Jiang, Jiapeng Jiang, Xinyu Miao, Weimin Mao, Meng Yan, Hongyang Lu Abstract Objectives: This study aims to achieve accurate differentiation of malignant pleural mesothelioma (MPM) from metastatic pleural disease (MPD) and to predict the…
Read MoreNarciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models
International Journal of Molecular Sciences 2025 October 17 [Link] Sicong Jiang, Serkan Berkcan, Nadja Perriraz-Mayer, Frédéric Triponez, Véronique Serre-Beinier Abstract Thoracic tumors, including lung adenocarcinoma (LUAD) and malignant pleural mesothelioma (MM), remain a leading cause of cancer-related deaths, primarily due to the challenges in treating advanced thoracic tumors. New drugs with optimal efficacy and minimal…
Read MoreUse of Patient-Derived Organoids for Pleural Mesothelioma 3D modelling
American Journal of Physiology Lung Cellular and Molecular Physiology 2025 October 29 [Link] Luca Volpini, Federica Monaco, Elisabetta Casalone, Elton Jalis Herman, Rebecca Filomena, Sandra Manzotti, Olga Strogovets, Gianluca Moroncini, Matteo Mozzicafreddo, Antonella Poloni, Elena Marinelli Busilacchi, Francesca Gonnelli, Francesca Barbisan, Gaia Goteri, Lina Zuccatosta, Martina Bonifazi, Giuseppe Matullo, Jiri Neuzil, Lory Santarelli, Najib M…
Read MoreDual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression
Cells 2025 October 15 [Link] Luca Hegedüs, Silvia Qaisieh, Christian Stülpnagel, Yavar Ganjeh Khor Dezfouli, Winny Tambo, Fabian Doerr, Natalie Baldes, Dirk Theegarten, Martin Schuler, Servet Bölükbas, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare cancer that often develops after a decades-long latency period and confers a grim prognosis. Novel, biomarker-based therapeutic modalities…
Read MoreNarciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models
International Journal of Molecular Sciences 2025 October 17 [Link] Sicong Jiang, Serkan Berkcan, Nadja Perriraz-Mayer, Frédéric Triponez, Véronique Serre-Beinier Abstract Thoracic tumors, including lung adenocarcinoma (LUAD) and malignant pleural mesothelioma (MM), remain a leading cause of cancer-related deaths, primarily due to the challenges in treating advanced thoracic tumors. New drugs with optimal efficacy and minimal…
Read MoreAnti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
Advanced Science 2025 October 24 [Link] Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang Abstract…
Read MorePD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma
Translational Lung Cancer Research 2025 September 30 [Link] Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka Abstract Background: Pleural mesothelioma (PM) is an uncommon malignancy with a poor prognosis, even after surgical resection. Programmed death-ligand 1 (PD-L1) expression is a potential prognostic biomarker in various…
Read MoreComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
Clinical Medicine Insights Oncology 2025 October 17 [Link] Doğan Bayram, Safa Can Efil, Serap Türk, Oğuz Kara, Serhat Sekmek, Şebnem Yücel, Selin Aktürk Esen, Gökhan Uçar, Oznur Bal, Efnan Algin, Doğan Uncu Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with…
Read More